ChiRhoStimÂ® (Human Secretin For Injection) Is Now Commercially Available
BURTONSVILLE, Md., Oct. 3, 2012 /PRNewswire/ -- ChiRhoClin, Inc. is pleased to notify the medical community that ChiRhoStim® (Human Secretin for Injection) has returned to the market. In cooperation with the FDA CDER Drug Shortage Team, ChiRhoClin is permitted to market the current batch of ChiRhoStim® until its new manufacturing site is operational by the beginning of 2013. ChiRhoStim® is an orphan drug product that aids in the diagnoses of pancreatic cancer and pancreatic exocrine dysfunction. ChiRhoStim® is approved for Pancreatic Function Testing, facilitating cannulation during ERCP, and Gastrinoma Testing. In addition, secretions of the pancreatic fluid after secretin stimulation can be used in situ for imaging modalities such as MRCP, CT, and EUS.
Skip Purich, VP of Marketing and Operations, said, "One of ChiRhoClin's main goals is to generate grants to help fund pancreatic research for the medical community. With the release of ChiRhoStim®, researchers studying the pancreas now have a tool that can facilitate their research."
ChiRhoClin is thankful to the FDA CDER Drug Shortage Team, pancreatic community, pharmacists, doctors, nurses, and especially the patients for their support and understanding during this drug shortage.
ChiRhoClin, Inc., a Maryland based family run corporation founded in 1991 by Dr. Edward D. Purich, is a research and development oriented pharmaceutical company focused on developing orphan drug products for the gastrointestinal and radiological community. Our emphasis is to develop orphan drug products that will diagnose and treat pancreatic gastrointestinal diseases and encourage research in the pancreatic area through our small pancreatic grant program.If you would like more information on ChiRhoStim® (Human Secretin for Injection), please visit www.ChiRhoStim.com or call 301-476-8388. Skip Purich VP of Marketing and Operations ChiRhoClin, Inc. SOURCE ChiRhoClin, Inc.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV